{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:10:06Z","timestamp":1790071806179,"version":"4.0.1"},"reference-count":54,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: Interleukin-6 (IL-6) is a pro-inflammatory cytokine implicated in the pathogenesis of SLE. Beyond its role in disease activity, IL-6 has also been associated with increased cardiovascular risk, potentially promoting endothelial dysfunction, atherosclerosis, and thromboinflammation. Our study aimed to investigate the associations between IL-6 levels, disease manifestations, organ damage, cardiovascular comorbidities, and treatment regimens in a cohort of SLE patients. Methods: A total of 88 SLE patients were recruited from the Rheumatology Clinic of the Clinical Rehabilitation Hospital, Ia\u0219i. Disease activity was assessed using the SLE Disease Activity Index (SLEDAI) and irreversible organ damage with the SLICC\/ACR Damage Index. Serum IL-6 levels were measured by ELISA. Statistical analyses included Mann\u2013Whitney U tests and Spearman correlation coefficients. Results: Among 88 SLE patients (89.8% female, mean age 51.9 \u00b1 14.8 years), 68.2% presented irreversible organ damage, most frequently cardiovascular (26.1%). Regarding disease manifestations, IL-6 was non-significantly elevated in patients with arthritis, rash, and low complement levels. Serum concentrations also tended to increase with disease severity, being higher in severe compared to moderate activity, and in moderate versus mild activity. Significant associations were found between IL-6 and hypertension (p = 0.027), aortic atherosclerosis (p = 0.034), menopausal status (p = 0.015), and hypercholesterolemia (p = 0.034). No significant differences were observed across treatment subgroups. Conclusions: IL-6 showed limited correlation with SLE clinical activity but was significantly elevated in patients with selected cardiovascular comorbidities. These findings suggest a potential contribution of IL-6 to cardiovascular risk in SLE, warranting further investigation in larger cohorts.<\/jats:p>","DOI":"10.3390\/jcm15135243","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:43:14Z","timestamp":1783345394000},"page":"5243","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["IL-6 in Systemic Lupus Erythematosus: At the Intersection of Disease Activity and Cardiovascular Risk"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1267-6134","authenticated-orcid":false,"given":"Patricia","family":"Richter","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Rehabilitation, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"I Rheumatology Clinic, Clinical Rehabilitation Hospital, 14 Pantelimon Halipa Street, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1155-7325","authenticated-orcid":false,"given":"Ciprian","family":"Rezus","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Grigore T. Popa University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania"},{"name":"III Internal Medicine Clinic, \u201cSt. Spiridon\u201d County Emergency Clinical Hospital, 1 Independence Boulevard, 700111 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"project-administration","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7313-3320","authenticated-orcid":false,"given":"Cristina","family":"Adam","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties I, II and III, Grigore T. Popa University of Medicine and Pharmacy, University Street No. 16, 700115 Iasi, Romania"},{"name":"Cardiovascular Rehabilitation Clinic, Clinical Rehabilitation Hospital, Pantelimon Halipa Street No. 14, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Mihai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Rehabilitation, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"I Rheumatology Clinic, Clinical Rehabilitation Hospital, 14 Pantelimon Halipa Street, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-4685","authenticated-orcid":false,"given":"Alexandra","family":"Burlui","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Rehabilitation, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"I Rheumatology Clinic, Clinical Rehabilitation Hospital, 14 Pantelimon Halipa Street, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rezus","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Rehabilitation, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"I Rheumatology Clinic, Clinical Rehabilitation Hospital, 14 Pantelimon Halipa Street, 700661 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Mercader-Salvans, J., Garc\u00eda-Gonz\u00e1lez, M., G\u00f3mez-Bernal, F., Quevedo-Abeledo, J.C., de Vera-Gonz\u00e1lez, A., Gonz\u00e1lez-Delgado, A., L\u00f3pez-Mej\u00edas, R., Mart\u00edn-Gonz\u00e1lez, C., Gonz\u00e1lez-Gay, M.\u00c1., and Ferraz-Amaro, I. (2023). Relationship between Disease Characteristics and Circulating Interleukin 6 in a Well-Characterized Cohort of Patients with Systemic Lupus Erythematosus. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241814006"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/art.43097","article-title":"Atherosclerotic Plaque Progression and Incident Cardiovascular Events in a 10-Year Prospective Study of Patients with Systemic Lupus Erythematosus: The Impact of Persistent Cardiovascular Risk Factor Target Attainment and Sustained DORIS Remission","volume":"77","author":"Papazoglou","year":"2025","journal-title":"Arthritis Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41392-025-02168-0","article-title":"Systemic Lupus Erythematosus: Updated Insights on the Pathogenesis, Diagnosis, Prevention and Therapeutics","volume":"10","author":"Dai","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1007\/s10067-023-06608-6","article-title":"Risk Factors for Cardiovascular Diseases in Patients with Systemic Lupus Erythematosus: An Umbrella Review","volume":"42","author":"Katayama","year":"2023","journal-title":"Clin. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s11883-023-01149-4","article-title":"Atherosclerosis in Systemic Lupus Erythematosus","volume":"25","author":"Tobin","year":"2023","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/joim.13557","article-title":"Systemic Lupus Erythematosus and Cardiovascular Disease","volume":"293","year":"2023","journal-title":"J. Intern. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.rdc.2022.02.003","article-title":"Managing Cardiovascular Risk in Patients with Rheumatic Disease","volume":"48","author":"Ferguson","year":"2022","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR Recommendations for Cardiovascular Risk Management in Rheumatic and Musculoskeletal Diseases, Including Systemic Lupus Erythematosus and Antiphospholipid Syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/CRD.0000000000000383","article-title":"Cardiovascular Disease in Patients with Systemic Lupus Erythematosus: Potential for Improved Primary Prevention with Statins","volume":"29","author":"Ballarano","year":"2021","journal-title":"Cardiol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s00198-025-07553-7","article-title":"The Link between Osteoporosis and Cardiovascular Diseases: A Review of Shared Mechanisms, Risk Factors, and Therapeutic Approaches","volume":"36","author":"Sharafi","year":"2025","journal-title":"Osteoporos. Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12265-026-10753-z","article-title":"Endothelial Dysfunction: Insights into Systemic Lupus Erythematosus-Associated Cardiovascular Disease and Neuropsychiatric Manifestations","volume":"19","author":"Butler","year":"2026","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1073\/pnas.82.16.5490","article-title":"Purification to Homogeneity and Characterization of Human B-Cell Differentiation Factor (BCDF or BSFp-2)","volume":"82","author":"Hirano","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Sporn, M.B., and Roberts, A.B. (1991). Interleukin-6. Peptide Growth Factors and Their Receptors I, Springer.","DOI":"10.1007\/978-1-4612-3210-0"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/324073a0","article-title":"Complementary DNA for a Novel Human Interleukin (BSF-2) That Induces B Lymphocytes to Produce Immunoglobulin","volume":"324","author":"Hirano","year":"1986","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V74.1.1.1","article-title":"The Biology of Interleukin-6","volume":"74","author":"Kishimoto","year":"1989","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/08830189809042997","article-title":"Interleukin 6 and Its Receptor: Ten Years Later","volume":"16","author":"Hirano","year":"1998","journal-title":"Int. Rev. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","article-title":"Recent Insights into Targeting the IL-6 Cytokine Family in Inflammatory Diseases and Cancer","volume":"18","author":"Jones","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/JLB.3MR0621-616RR","article-title":"Role of IL-6 in Dendritic Cell Functions","volume":"111","author":"Xu","year":"2022","journal-title":"J. Leukoc. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.jhep.2016.02.004","article-title":"IL-6 Pathway in the Liver: From Physiopathology to Therapy","volume":"64","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_20","unstructured":"Hochberg, M.C., Gravallese, E.M., Smolen, J.S., van der Heijde, D., Weinblatt, M.E., and Weisman, M.H. (2022). Pathogenesis of Systemic Lupus Erythematosus. Rheumatology, Elsevier."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1038\/s41598-018-20947-4","article-title":"The Model of Circulating Immune Complexes and Interleukin-6 Improves the Prediction of Disease Activity in Systemic Lupus Erythematosus","volume":"8","author":"Thanadetsuntorn","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Pesqueda-Cendejas, K., Rivera-Escoto, M., Meza-Meza, M.R., Campos-L\u00f3pez, B., Parra-Rojas, I., Montoya-Buelna, M., and De la Cruz-Mosso, U. (2023). Nutritional Approaches to Modulate Cardiovascular Disease Risk in Systemic Lupus Erythematosus: A Literature Review. Nutrients, 15.","DOI":"10.3390\/nu15041036"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"152468","DOI":"10.1016\/j.semarthrit.2024.152468","article-title":"Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus","volume":"67","author":"Choi","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.amjmed.2022.11.016","article-title":"Renin-Angiotensin System-Modifying Antihypertensive Drugs Can Reduce the Risk of Cardiovascular Complications in Lupus: A Retrospective Cohort Study","volume":"136","author":"Hurst","year":"2023","journal-title":"Am. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1080\/14656566.2020.1770227","article-title":"Management of Cardiovascular Disease in Patients with Systemic Lupus Erythematosus","volume":"21","author":"Piranavan","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s10753-021-01455-6","article-title":"Understanding Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Toward Better Treatment and Prevention","volume":"44","author":"Reiss","year":"2021","journal-title":"Inflammation"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Richter, P., Rezus, C., Burlui, A.M., Schreiner, T.G., and Rezus, E. (2025). Serum Interleukin-6 in Systemic Lupus Erythematosus: Insights into Immune Dysregulation, Disease Activity, and Clinical Manifestations. Cells, 14.","DOI":"10.3390\/cells14191568"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology Revised Criteria for the Classification of Systemic Lupus Erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and Validation of Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 EULAR\/ACR Classification Criteria for Systemic Lupus Erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.1780350606","article-title":"Derivation of the Sledai. A Disease Activity Index for Lupus Patients","volume":"35","author":"Bombardier","year":"1992","journal-title":"Arthritis Rheum."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"102615","DOI":"10.1016\/j.jaut.2021.102615","article-title":"Clinical Disease Activity and Flare in SLE: Current Concepts and Novel Biomarkers","volume":"119","author":"Thanou","year":"2021","journal-title":"J. Autoimmun."},{"key":"ref_33","first-page":"1820","article-title":"Systemic Lupus International Collaborative Clinics: Development of a Damage Index in Systemic Lupus Erythematosus","volume":"19","author":"Gladman","year":"1992","journal-title":"J. Rheumatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/art.1780390303","article-title":"The Development and Initial Validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology Damage Index for Systemic Lupus Erythematosus","volume":"39","author":"Gladman","year":"1996","journal-title":"Arthritis Rheum."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/art.1780400506","article-title":"The Reliability of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology Damage Index in Patients with Systemic Lupus Erythematosus","volume":"40","author":"Gladman","year":"1997","journal-title":"Arthritis Rheum."},{"key":"ref_36","first-page":"373","article-title":"The Systemic Lupus International Collaborating Clinics\/American College of Rheumatology (SLICC\/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison","volume":"27","author":"Gladman","year":"2000","journal-title":"J. Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1177\/09612033231209601","article-title":"Active Lupus in Argentina: Results of a Multicenter and National Registry","volume":"32","author":"Quintana","year":"2023","journal-title":"Lupus"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1177\/09612033221129776","article-title":"Residual Disease Activity and Treatment Intensification in Systemic Lupus Erythematosus: A Cross-Sectional Study to Quantify the Need for New Therapies","volume":"31","author":"Gioti","year":"2022","journal-title":"Lupus"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/acr.23109","article-title":"Defining Low Disease Activity in Systemic Lupus Erythematosus","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e1801","DOI":"10.6061\/clinics\/2020\/e1801","article-title":"Serum Interleukin-6 Level Is Correlated with the Disease Activity of Systemic Lupus Erythematosus: A Meta-Analysis","volume":"75","author":"Ding","year":"2020","journal-title":"Clinics"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1177\/09612033221102575","article-title":"Role of Interleukin-6 and Interferon-\u03b1 in Systemic Lupus Erythematosus: A Case-Control Study and Meta-Analysis","volume":"31","author":"Pattanaik","year":"2022","journal-title":"Lupus"},{"key":"ref_42","first-page":"2867","article-title":"Changes of Serum IL-6, IL-10 and TNF-\u03b1 Levels in Patients with Systemic Lupus Erythematosus and Their Clinical Value","volume":"13","author":"Jin","year":"2021","journal-title":"Am. J. Transl. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cyto.2015.05.007","article-title":"The Role of Serum IL-17 and IL-6 as Biomarkers of Disease Activity and Predictors of Remission in Patients with Lupus Nephritis","volume":"76","author":"Ezzeldin","year":"2015","journal-title":"Cytokine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"101896","DOI":"10.1016\/j.berh.2023.101896","article-title":"Assessment of Disease Activity and Damage in SLE: Are We There Yet?","volume":"37","author":"Cruciani","year":"2023","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/s12276-021-00649-0","article-title":"Interplay between Interleukin-6 Signaling and the Vascular Endothelium in Cytokine Storms","volume":"53","author":"Kang","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0014-5793(97)00487-0","article-title":"Repression of Interleukin-6 Gene Expression by 17 Beta-Estradiol: Inhibition of the DNA-Binding Activity of the Transcription Factors NF-IL6 and NF-Kappa B by the Estrogen Receptor","volume":"409","author":"Ray","year":"1997","journal-title":"FEBS Lett."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1172\/JCI117100","article-title":"17 Beta-Estradiol Inhibits Expression of Human Interleukin-6 Promoter-Reporter Constructs by a Receptor-Dependent Mechanism","volume":"93","author":"Pottratz","year":"1994","journal-title":"J. Clin. Investig."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jacc.2019.12.049","article-title":"Menopause-Related Estrogen Decrease and the Pathogenesis of HFpEF","volume":"75","author":"Sabbatini","year":"2020","journal-title":"JACC"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1677\/joe.0.1720387","article-title":"Effects of Oestrogen Deprivation on Interleukin-6 Production by Peripheral Blood Mononuclear Cells of Postmenopausal Women","volume":"172","author":"Wieckiewicz","year":"2002","journal-title":"J. Endocrinol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Abildgaard, J., Tingstedt, J., Zhao, Y., Hartling, H.J., Pedersen, A.T., Lindegaard, B., and Dam Nielsen, S. (2020). Increased Systemic Inflammation and Altered Distribution of T-Cell Subsets in Postmenopausal Women. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0235174"},{"key":"ref_51","first-page":"571","article-title":"Clinical Significance of Serum and Urinary Interleukin-6 in Systemic Lupus Erythematosus Patients","volume":"39","author":"Dima","year":"2017","journal-title":"Egypt. Rheumatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"10175","DOI":"10.1038\/s41598-022-14571-6","article-title":"Effect of Add-on Hydroxychloroquine Therapy on Serum Proinflammatory Cytokine Levels in Patients with Systemic Lupus Erythematosus","volume":"12","author":"Wakiya","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Parodis, I., \u00c5kerstr\u00f6m, E., Sj\u00f6wall, C., Sohrabian, A., J\u00f6nsen, A., Gomez, A., Frodlund, M., Zickert, A., Bengtsson, A.A., and R\u00f6nnelid, J. (2020). Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21103463"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.bbrc.2017.10.037","article-title":"Mycophenolic Mofetil, an Alternative Antiviral and Immunomodulator for the Highly Pathogenic Avian Influenza H5N1 Virus Infection","volume":"494","author":"Cho","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5243\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:39:40Z","timestamp":1790069980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":54,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15135243"],"URL":"https:\/\/doi.org\/10.3390\/jcm15135243","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]}}}